CTOs on the Move

ThromboGenics

www.thrombogenics.com

 
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Tanis Technical

Tanis Technical is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmacosmos

Pharmacosmos A/S is specialized in iron therapy. We develop, manufacture and market medicines for treatment of iron deficiency anaemia in humans and animals.

NextGen Pharma Technologies

NextGen Pharma Technologies is a Colorado Springs, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharma Test-Americas

Pharma Test-Americas is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope

Neurotrope is discovering restorative therapeutics for patients with life-altering neurodegenerative diseases and development disorders. We are a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer`s Disease, Fragile X Syndrome and Niemann-Pick Type C